Pharm Exec: Biopharma in 2021 Big Gains, Volatile Values (Young & Partners article – March 2022)Devin Maraj2022-03-12T02:24:09+00:00March 11th, 2022|Featured, Our Publications|
Chemicals M&A to be resilient in 2022 (ICIS Chemical Business February 11 – February 17 2022)Devin Maraj2022-02-18T20:54:48+00:00February 18th, 2022|Featured, Our Publications|
New Supply Chains (ICIS Chemical Business November 26 – December 2 2021)Devin Maraj2021-12-03T19:56:38+00:00December 3rd, 2021|Featured, Our Publications|
Chemical Economic, M&A and Financing (ICIS Chemical Business November 19-26 2021)Devin Maraj2021-11-22T17:29:34+00:00November 22nd, 2021|Featured, Our Publications|
Pharm Exec: Doubling Down On Innovation, Recovery (Young & Partners article – September 2021)Devin Maraj2021-09-16T20:12:39+00:00September 16th, 2021|Featured, Our Publications|
Mixed outlook for chemical financing (ICIS Chemical Business August 27, 2021)Devin Maraj2021-08-30T15:23:56+00:00August 27th, 2021|Featured, Our Publications|
Chemical M&A market in transition (ICIS Chemical Business August 20, 2021)Devin Maraj2021-08-30T15:00:20+00:00August 20th, 2021|Featured, Our Publications|
Pharm Exec: Pharma and Biotech’s 2020 Full-Year View (Young & Partners article – March 2021)news2021-05-28T16:06:59+00:00March 18th, 2021|Featured, Our Publications|
Chemical Industry Financings in 2020 and Outlook (ICIS Chemical Business February 26, 2021)news2021-05-28T16:06:43+00:00March 1st, 2021|Featured, Our Publications|
Chemical M&A – Yearend Summary and Forecast (ICIS Chemical Business, Feb 12, 2021 issue)news2021-05-28T16:07:03+00:00February 26th, 2021|Featured, Our Publications|
